Isotechnika Pharma Inc IPHAF

RE: RE: RE: RE: RE: Goodman gone

[MementoMori]

> 90% ofthe valuation will be based on the Lux royalty agreement.

Can you tell us why you think so? The market for psoriasis is many times larger than the market Lux is bringing and the psoriasis market seems to be almost within reach (unliketransplant, which still requires massive financing for more,difficult trials). I think you'd be totally crazy to sell ISA based mainly on the value of the Lux deal. It would be like selling your car based mainly on the value of the tires.

(BTW, don't forget that the transplant market is HUGE. That's where the real money is, if ISA could only get to it. Notwithstanding the challenges, I cannot imagine and have seen no evidence that ISA has simply written it off.)

I am extremely doubtful that management wants to sell the company. As far as I am aware, they have never hinted that this is their intention, and certainly Foster, at least, has implied many times (at almost every annual meeting) that it his intention to take the company all the way to their original market. Perhaps Paladin would prefer a sale (though as far as I know we have no evidence that it does, either) but Paladin is still a minority shareholder, not able to simply decree what will happen.